TD;LR: Kisspeptin may affect how we act and feel. It seems plausible that a TRT-induced reduction in this hormone is a problem for some men.
I’d previously asked if suppression of GnRH by TRT is a problem. The literature at least hints that it is possible. The situation with kisspeptin may be similar. The kisspeptin hormone sits near the top of the male sex hormone cascade. It helps stimulate GnRH production, which in turn leads to LH and FSH, which leads to testosterone and then estradiol. Testosterone and estradiol then provide negative feedback for kisspeptin production in the hypothalamus. Testosterone replacement therapy tends to swamp this feedback mechanism, leading to a presumed suppression of hypothalamic kisspeptin and the other intermediate hormones. However, there are other sources of kisspeptin, albeit maybe smaller ones. These include the hippocampus and the adrenal gland. This leaves uncertainly about the importance of the likely reduction in kisspeptin caused by TRT. Nonetheless, it may be that due to inter-individual variably some men tolerate the reduction, while others have issues.
What issues? This review article lays out some possibilities. After explaining kisspeptin’s role in GnRH production, the authors say “… kisspeptin signaling is not limited to the hypothalamus but also occurs in other extrahypothalamic brain regions. It is these locations for kisspeptin signaling that gave the first clues to kisspeptin’s role in sexual and emotional processing.” In particular, in various species there’s “a role for kisspeptin in behavioral networks related to reproduction including olfaction, audition, fear, anxiety, mood, and sexual arousal.”
Of particular interest are the references to anxiety, mood and libido. These are common problem areas. It is encouraging that experiments on men yielded some positive results:
So we have some hints of the potential importance of kisspeptin. While speculative, it seems possible that kisspeptin suppression via TRT can have detrimental effects. If so then the next question is, can these problems be resolved by supplementation? Further research is needed to give us some answers.
__________________________________
From Admin:
If you have been on testosterone replacement therapy and still find yourself asking why your libido, mood, or overall sense of well-being is not where you expected it to be, there is a piece of your hormonal architecture that rarely gets discussed outside of academic papers. That piece is kisspeptin, a neuropeptide that sits at the very top of the male reproductive hormone cascade. Understanding the kisspeptin peptide is increasingly important for men managing TRT, for those exploring alternatives to hCG, and for anyone trying to make sense of why testosterone alone does not always fix everything.
Kisspeptin is not new to science, but it is only now moving from research labs to clinical conversations. Two 2023 randomized clinical trials published in JAMA Network Open demonstrated that kisspeptin can directly improve sexual brain processing and physical arousal in men with low sexual desire. A follow-up 2025 study showed it can be delivered non-invasively through an intranasal spray. This article synthesizes the current evidence, explains how TRT interacts with kisspeptin signaling, and gives you a clear picture of where this peptide actually fits in a men's health protocol.
In practical terms, kisspeptin is the gatekeeper. Without adequate kisspeptin signaling, GnRH neurons remain largely silent. No kisspeptin pulse, no GnRH, no LH, no testosterone. This is why researchers describe it as the 'master regulator' of the hypothalamic-pituitary-gonadal (HPG) axis.
The kisspeptin family includes four biologically active isoforms: KP-54 (the most abundant, also called kisspeptin-54 or metastin), KP-14, KP-13, and KP-10 (the minimal ten-amino-acid fragment that retains full KISS1R binding). All four are derived through proteolytic cleavage of a larger precursor protein called prepro-kisspeptin. In research settings, both KP-54 and KP-10 have been studied in humans, though KP-54 has been used more extensively in clinical trials.
What makes kisspeptin particularly interesting from a pharmacological standpoint is its pulsatile, self-limiting signaling pattern. Unlike continuous GnRH infusions, which desensitize pituitary receptors, kisspeptin activates endogenous feedback loops without causing long-term receptor burnout. This makes it a physiologically anchored option compared with synthetic GnRH analogs that require careful titration to avoid shutting down the axis entirely.
The clinically important question is whether that kisspeptin suppression matters beyond the loss of LH and FSH. And the answer appears to be: yes, for some men it does. Kisspeptin neurons in the hypothalamus project not only to GnRH neurons but also to extrahypothalamic brain regions involved in emotional processing, olfaction, fear, mood, and sexual arousal - including the medial amygdala and the bed nucleus of the stria terminalis. This dual role means kisspeptin is not purely a reproductive hormone. It is also a neuromodulator with measurable effects on sexual motivation and mood.
Members in our forum have raised this exact concern since at least 2020. One long-running thread notes that testosterone replacement 'does not restore psychosexual function to the same level as age-matched controls,' citing data from a clinical talk on kisspeptin-HPG integration. Members who added hCG to TRT often reported subjective libido improvements that went beyond what testosterone levels alone would predict - and kisspeptin suppression may be part of that explanation, since hCG indirectly supports some intratesticular signaling that the kisspeptin pathway would otherwise have coordinated.
That said, kisspeptin suppression under TRT is one variable among many. Other men on TRT report that their libido improved dramatically and never looked back. Individual variability in KISS1R receptor sensitivity, adrenal kisspeptin production, and baseline psychosexual health all contribute. The key point is that for men who have optimized their testosterone, estradiol, and thyroid levels but still find libido elusive, kisspeptin physiology is worth understanding.
The results were striking. Kisspeptin significantly boosted brain activity in key structures of the sexual brain network compared with placebo. Penile rigidity increased by up to 56% compared with placebo while participants viewed erotic content. Psychometric analysis showed that kisspeptin improved self-reported 'happiness about sex' - a patient-centered outcome. Notably, the men who were most distressed by their low sexual desire showed the greatest response, suggesting kisspeptin works most powerfully when the underlying pathway is most impaired.
These are not testosterone-mediated effects. Baseline testosterone levels in the HSDD cohort were within the normal reference range, meaning kisspeptin was acting through its central behavioral pathways - not simply by boosting circulating androgens. This is the strongest human evidence to date that kisspeptin plays a direct role in male sexual desire and arousal independent of gonadal hormone levels.
The study - a randomized, double-blinded, crossover, placebo-controlled trial across healthy men and women - demonstrated that intranasal kisspeptin-54 rapidly and dose-dependently stimulated LH release. In healthy men, maximal LH rises occurred within 30 minutes of intranasal administration. Crucially, no adverse events or side effects were encountered. The researchers also confirmed pharmaceutical stability of the intranasal formulation and identified a novel olfactory-to-hypothalamic pathway by which the nasal route accesses GnRH neurons directly.
This is a genuinely important development. If kisspeptin can be delivered as a nasal spray with reliable hormonal effects and a clean safety profile, it moves from a research-grade injectable to something approaching clinical utility. The same team had previously shown in 2021 conference data that intranasal KP-54 dose-dependently increased LH within 30-45 minutes in healthy men - the 2025 paper is the full peer-reviewed confirmation of that work.
hCG (human chorionic gonadotropin) works at the testicular level, directly mimicking LH to stimulate Leydig cell testosterone production and maintain intratesticular testosterone concentration. It bypasses the suppressed HPG axis entirely. That is exactly what you want during TRT to prevent testicular atrophy and preserve some of the benefits of endogenous signaling.
Kisspeptin, by contrast, works at the hypothalamic level - at the very top of the axis. During TRT, the axis is suppressed by negative feedback from exogenous testosterone. That suppression blunts the downstream effect of any kisspeptin signal, because GnRH neurons and the pituitary are already receiving strong 'stop' signals. Kisspeptin essentially tries to push against a locked door when TRT is on board.
The comparison table below summarizes how these three compounds differ in their mechanism, utility during TRT, and current regulatory status.
Nelson Vergel has noted in forum discussions over the years that kisspeptin is not a gonadotropin replacement. Its potential role is distinct: improving central sexual motivation and mood through extrahypothalamic pathways, not substituting for hCG's peripheral testicular effects. These are complementary mechanisms, not competing ones.
In late 2023, the FDA moved 19 peptides - including kisspeptin-10 - to Category 2 under the interim 503A bulks list. Category 2 means the FDA has identified 'significant safety risks' pending further evaluation and will not extend the non-enforcement policy that applies to Category 1 substances. In practical terms, 503A compounding pharmacies cannot legally compound kisspeptin-10 under the Category 2 designation. The October 2024 FDA Pharmacy Compounding Advisory Committee (PCAC) meeting specifically reviewed kisspeptin-10 for potential inclusion on the 503A bulks list.
In February 2026, HHS Secretary RFK Jr. announced a plan to reclassify 14 of the 19 restricted peptides back to Category 1 - and kisspeptin-10 is explicitly included in that list. As of May 2026, no formal FDA rulemaking has been published finalizing that reclassification, but the policy direction is clear. Five other peptides were already removed from Category 2 in September 2024 after their nominators withdrew their nominations. If the announced reclassification moves forward, kisspeptin-10 would once again become available from licensed 503A compounding pharmacies with a valid prescription.
Until formal reclassification is finalized, access to compounded kisspeptin-10 in the United States remains legally limited. Any pharmacy offering it under current Category 2 status is operating outside FDA compliance. Monitor the FDA 503A bulks list and ExcelMale forum threads for updates as this regulatory situation continues to evolve.
1. Kisspeptin Suppression Under TRT: Can It Affect Mood and Libido? - The foundational thread exploring how TRT-induced kisspeptin suppression may explain persistent libido and mood issues for some men.
2. Novel Therapeutic Avenues for Kisspeptin - A deep-dive thread covering emerging research on kisspeptin's expanding clinical applications.
3. Kisspeptin Dosage: What the Research Shows - Community discussion on translating nmol/kg research doses into practical microgram amounts.
4. FDA Decides Not to Allow Kisspeptin-10 Manufacturing by Compounding Pharmacies - Thread covering the Category 2 classification and its impact on compounding access.
5. Kisspeptin-10 as a Replacement for Compounded hCG? - Discussion on whether kisspeptin can substitute for hCG during TRT and why it likely cannot.
6. Anyone Succeeding in Increasing Testosterone With Kisspeptin While on TRT? - Member experiences using kisspeptin alongside exogenous testosterone.
7. Kisspeptin-10 Instead of hCG - Practical thread comparing kisspeptin-10 and hCG for men seeking alternatives.
8. Investigating the Detection of Kisspeptin-10 in Urine (Sports/Doping Angle) - Thread covering detection methods relevant to men involved in competitive sports.
10. Thurston L et al. Effects of kisspeptin administration in women with hypoactive sexual desire disorder: a randomized clinical trial. JAMA Network Open. 2022;5:e2236131. https://doi.org/10.1001/jamanetworkopen.2022.36131
11. Mills EG et al. Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humans. eBioMedicine. 2025;105689. https://doi.org/10.1016/j.ebiom.2025.105689
12. Comninos AN et al. Kisspeptin modulates sexual and emotional brain processing in humans. J Clin Invest. 2017;127:709-719. https://doi.org/10.1172/JCI89519
13. Ertl N et al. Women and men with distressing low sexual desire exhibit sexually dimorphic brain processing. Sci Rep. 2024;14:11051. https://doi.org/10.1038/s41598-024-61547-9
14. Jayasena CN et al. Can kisspeptin be a new treatment for sexual dysfunction? Trends Endocrinol Metab. 2025. https://doi.org/10.1016/j.tem.2025.02.007
15. Navarro VM. Interactions between kisspeptins and neurokinin B. Adv Exp Med Biol. 2013;784:325-347. https://doi.org/10.1007/978-1-4614-6199-9_15
16. Seminara SB et al. The GPR54 gene as a regulator of puberty. N Engl J Med. 2003;349:1614-1627. https://doi.org/10.1056/NEJMoa035322
17. FDA Pharmacy Compounding Advisory Committee Briefing Document: Kisspeptin-10. October 29, 2024. https://www.fda.gov/media/182089/download
18. McBride JA, Coward RM. Recovery of spermatogenesis following testosterone replacement therapy or anabolic-androgenic steroid use. Asian J Androl. 2016;18:373-380. https://doi.org/10.4103/1008-682X.173938
The clinical evidence from Imperial College London's randomized trials is now strong enough to take seriously. For men with HSDD who have normal testosterone levels, kisspeptin improved sexual brain processing and penile rigidity meaningfully. The intranasal delivery route opens a practical path that intravenous infusions could not. And while regulatory access remains restricted in the United States as of mid-2026, the announced reclassification signals that kisspeptin-10 compounding access may return in the near term.
For men on TRT who want to explore every variable affecting libido and sexual function, kisspeptin is worth tracking. The ExcelMale forum threads listed above contain years of member-level discussion that complements the peer-reviewed record well. As always, any decision to explore off-label peptide use should involve a knowledgeable physician and baseline blood work.
Medical Disclaimer
This article is for educational purposes only and does not constitute medical advice. Kisspeptin-10 is not FDA-approved for any indication and its compounding status under 503A is currently restricted. Always consult a qualified healthcare provider before starting or modifying any hormone therapy, peptide protocol, or medical treatment. References to regulatory developments reflect information available as of May 2026 and are subject to change.
About ExcelMale.com
ExcelMale.com is one of the world's largest and most respected men's health forums, with over 24,000 members and more than 20 years of peer-moderated discussion on testosterone replacement therapy, hormone optimization, peptides, sexual health, and longevity. The forum was founded and is curated by Nelson Vergel, chemical engineer, 30+ year TRT patient, and author of Testosterone: A Man's Guide and Beyond Testosterone. Nelson's work bridges peer-reviewed research and real-world patient experience in a way that no purely academic source can match.
I’d previously asked if suppression of GnRH by TRT is a problem. The literature at least hints that it is possible. The situation with kisspeptin may be similar. The kisspeptin hormone sits near the top of the male sex hormone cascade. It helps stimulate GnRH production, which in turn leads to LH and FSH, which leads to testosterone and then estradiol. Testosterone and estradiol then provide negative feedback for kisspeptin production in the hypothalamus. Testosterone replacement therapy tends to swamp this feedback mechanism, leading to a presumed suppression of hypothalamic kisspeptin and the other intermediate hormones. However, there are other sources of kisspeptin, albeit maybe smaller ones. These include the hippocampus and the adrenal gland. This leaves uncertainly about the importance of the likely reduction in kisspeptin caused by TRT. Nonetheless, it may be that due to inter-individual variably some men tolerate the reduction, while others have issues.
What issues? This review article lays out some possibilities. After explaining kisspeptin’s role in GnRH production, the authors say “… kisspeptin signaling is not limited to the hypothalamus but also occurs in other extrahypothalamic brain regions. It is these locations for kisspeptin signaling that gave the first clues to kisspeptin’s role in sexual and emotional processing.” In particular, in various species there’s “a role for kisspeptin in behavioral networks related to reproduction including olfaction, audition, fear, anxiety, mood, and sexual arousal.”
Of particular interest are the references to anxiety, mood and libido. These are common problem areas. It is encouraging that experiments on men yielded some positive results:
“… peripheral kisspeptin administration to healthy men reduces negative mood…”
“These data from rodent, zebrafish, and human studies therefore implicate kisspeptin signaling in the modulation of mood and anxiety with antidepressant-like effects which may have clinical implications.”
“This suggests that kisspeptin signaling could enhance reward-system activity during sexual arousal (particularly in those generally less responsive to reward), thereby triggering a desire for sexual activity and possibly subsequent reproduction.”
“It is therefore possible, that other factors are also important in modulating libido that may include upstream kisspeptin signaling. Certainly, the expression pattern of kisspeptin and its cognate receptor in limbic and paralimbic structures would point towards this as well as the more recent studies identifying a role in sexual brain processing and erection generation. Further studies are required to determine if kisspeptin signaling could be exploited in future therapies for patients with sexual and emotional disorders.”
So we have some hints of the potential importance of kisspeptin. While speculative, it seems possible that kisspeptin suppression via TRT can have detrimental effects. If so then the next question is, can these problems be resolved by supplementation? Further research is needed to give us some answers.
__________________________________
From Admin:
What Is the Kisspeptin Peptide and How Does It Affect Testosterone, Libido, and Sexual Function in Men?
Curated by Nelson Vergel | ExcelMale.com | May 2026Key Takeaways |
• Kisspeptin is the upstream master regulator of the HPG axis, triggering the GnRH-LH-testosterone cascade in men. • Exogenous testosterone (TRT) suppresses hypothalamic kisspeptin, which may partly explain why some men on TRT still struggle with low libido or mood. • A 2023 JAMA Network Open randomized controlled trial found kisspeptin increased penile rigidity by up to 56% and improved sexual brain network activity in men with hypoactive sexual desire disorder (HSDD). • A landmark 2025 study published in eBioMedicine demonstrated that intranasal kisspeptin-54 rapidly and dose-dependently stimulates LH release in healthy men without side effects. • Kisspeptin is NOT a functional replacement for hCG during TRT: it works upstream where the axis is suppressed. hCG bypasses suppression at the testicular level. • As of early 2026, kisspeptin-10 remains Category 2 under FDA compounding rules, but reclassification back to Category 1 has been announced as a priority under the current HHS administration. |
If you have been on testosterone replacement therapy and still find yourself asking why your libido, mood, or overall sense of well-being is not where you expected it to be, there is a piece of your hormonal architecture that rarely gets discussed outside of academic papers. That piece is kisspeptin, a neuropeptide that sits at the very top of the male reproductive hormone cascade. Understanding the kisspeptin peptide is increasingly important for men managing TRT, for those exploring alternatives to hCG, and for anyone trying to make sense of why testosterone alone does not always fix everything.
Kisspeptin is not new to science, but it is only now moving from research labs to clinical conversations. Two 2023 randomized clinical trials published in JAMA Network Open demonstrated that kisspeptin can directly improve sexual brain processing and physical arousal in men with low sexual desire. A follow-up 2025 study showed it can be delivered non-invasively through an intranasal spray. This article synthesizes the current evidence, explains how TRT interacts with kisspeptin signaling, and gives you a clear picture of where this peptide actually fits in a men's health protocol.
How Does the Kisspeptin Peptide Control Testosterone Production?
Kisspeptin is produced primarily by specialized neurons in the hypothalamus and is encoded by the KISS1 gene. It binds to the KISS1 receptor (also called GPR54) on GnRH neurons, triggering a pulsatile release of gonadotropin-releasing hormone (GnRH). That GnRH pulse then drives the pituitary to secrete luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn signal the Leydig cells in the testes to produce testosterone.In practical terms, kisspeptin is the gatekeeper. Without adequate kisspeptin signaling, GnRH neurons remain largely silent. No kisspeptin pulse, no GnRH, no LH, no testosterone. This is why researchers describe it as the 'master regulator' of the hypothalamic-pituitary-gonadal (HPG) axis.
The kisspeptin family includes four biologically active isoforms: KP-54 (the most abundant, also called kisspeptin-54 or metastin), KP-14, KP-13, and KP-10 (the minimal ten-amino-acid fragment that retains full KISS1R binding). All four are derived through proteolytic cleavage of a larger precursor protein called prepro-kisspeptin. In research settings, both KP-54 and KP-10 have been studied in humans, though KP-54 has been used more extensively in clinical trials.
What makes kisspeptin particularly interesting from a pharmacological standpoint is its pulsatile, self-limiting signaling pattern. Unlike continuous GnRH infusions, which desensitize pituitary receptors, kisspeptin activates endogenous feedback loops without causing long-term receptor burnout. This makes it a physiologically anchored option compared with synthetic GnRH analogs that require careful titration to avoid shutting down the axis entirely.
Does TRT Suppress Kisspeptin, and Why Does That Matter for Libido?
This question has been discussed extensively in the ExcelMale community for years, and the answer is almost certainly yes. TRT introduces exogenous testosterone, which creates a powerful negative feedback signal at the hypothalamus. Testosterone and its aromatized metabolite estradiol suppress hypothalamic kisspeptin production, which in turn blunts GnRH pulsatility. The entire axis downstream - LH, FSH, intratesticular testosterone - goes quiet.The clinically important question is whether that kisspeptin suppression matters beyond the loss of LH and FSH. And the answer appears to be: yes, for some men it does. Kisspeptin neurons in the hypothalamus project not only to GnRH neurons but also to extrahypothalamic brain regions involved in emotional processing, olfaction, fear, mood, and sexual arousal - including the medial amygdala and the bed nucleus of the stria terminalis. This dual role means kisspeptin is not purely a reproductive hormone. It is also a neuromodulator with measurable effects on sexual motivation and mood.
Members in our forum have raised this exact concern since at least 2020. One long-running thread notes that testosterone replacement 'does not restore psychosexual function to the same level as age-matched controls,' citing data from a clinical talk on kisspeptin-HPG integration. Members who added hCG to TRT often reported subjective libido improvements that went beyond what testosterone levels alone would predict - and kisspeptin suppression may be part of that explanation, since hCG indirectly supports some intratesticular signaling that the kisspeptin pathway would otherwise have coordinated.
That said, kisspeptin suppression under TRT is one variable among many. Other men on TRT report that their libido improved dramatically and never looked back. Individual variability in KISS1R receptor sensitivity, adrenal kisspeptin production, and baseline psychosexual health all contribute. The key point is that for men who have optimized their testosterone, estradiol, and thyroid levels but still find libido elusive, kisspeptin physiology is worth understanding.
What Does the Latest Clinical Research Show About Kisspeptin and Male Sexual Function?
The strongest clinical data comes from the team at Imperial College London, who have conducted a series of randomized, double-blind, placebo-controlled trials specifically examining kisspeptin's effects on sexual function in humans. Their work shifted the conversation from animal models to human clinical relevance.The 2023 JAMA Network Open Trial in Men With HSDD
A landmark 2023 randomized clinical trial (Mills EG et al., JAMA Network Open, 2023) enrolled 32 heterosexual men with a confirmed diagnosis of hypoactive sexual desire disorder (HSDD). Participants received either a kisspeptin infusion or placebo in a crossover design, followed by brain fMRI scanning and measurement of penile rigidity while viewing erotic video.The results were striking. Kisspeptin significantly boosted brain activity in key structures of the sexual brain network compared with placebo. Penile rigidity increased by up to 56% compared with placebo while participants viewed erotic content. Psychometric analysis showed that kisspeptin improved self-reported 'happiness about sex' - a patient-centered outcome. Notably, the men who were most distressed by their low sexual desire showed the greatest response, suggesting kisspeptin works most powerfully when the underlying pathway is most impaired.
These are not testosterone-mediated effects. Baseline testosterone levels in the HSDD cohort were within the normal reference range, meaning kisspeptin was acting through its central behavioral pathways - not simply by boosting circulating androgens. This is the strongest human evidence to date that kisspeptin plays a direct role in male sexual desire and arousal independent of gonadal hormone levels.
The 2025 Breakthrough: Intranasal Kisspeptin Works in Humans
Until recently, kisspeptin administration in humans required intravenous or subcutaneous injection, both of which create real barriers to clinical use. A 2025 study published in eBioMedicine (Mills EG et al., DOI: 10.1016/j.ebiom.2025.105689) changed that picture significantly.The study - a randomized, double-blinded, crossover, placebo-controlled trial across healthy men and women - demonstrated that intranasal kisspeptin-54 rapidly and dose-dependently stimulated LH release. In healthy men, maximal LH rises occurred within 30 minutes of intranasal administration. Crucially, no adverse events or side effects were encountered. The researchers also confirmed pharmaceutical stability of the intranasal formulation and identified a novel olfactory-to-hypothalamic pathway by which the nasal route accesses GnRH neurons directly.
This is a genuinely important development. If kisspeptin can be delivered as a nasal spray with reliable hormonal effects and a clean safety profile, it moves from a research-grade injectable to something approaching clinical utility. The same team had previously shown in 2021 conference data that intranasal KP-54 dose-dependently increased LH within 30-45 minutes in healthy men - the 2025 paper is the full peer-reviewed confirmation of that work.
Is Kisspeptin a Replacement for hCG on TRT? A Clear Comparison
This is one of the most common questions that comes up in the ExcelMale forum, and the honest answer is: not really, and here is why.hCG (human chorionic gonadotropin) works at the testicular level, directly mimicking LH to stimulate Leydig cell testosterone production and maintain intratesticular testosterone concentration. It bypasses the suppressed HPG axis entirely. That is exactly what you want during TRT to prevent testicular atrophy and preserve some of the benefits of endogenous signaling.
Kisspeptin, by contrast, works at the hypothalamic level - at the very top of the axis. During TRT, the axis is suppressed by negative feedback from exogenous testosterone. That suppression blunts the downstream effect of any kisspeptin signal, because GnRH neurons and the pituitary are already receiving strong 'stop' signals. Kisspeptin essentially tries to push against a locked door when TRT is on board.
The comparison table below summarizes how these three compounds differ in their mechanism, utility during TRT, and current regulatory status.
Feature | Kisspeptin | hCG | Gonadorelin |
Where it acts | Hypothalamus (upstream) | Testes (direct LH mimic) | Pituitary (GnRH pulse) |
Stimulates testosterone | Indirectly via GnRH/LH | Yes - direct Leydig cell stimulation | Yes - via LH/FSH release |
Effective during TRT? | Limited - axis is suppressed | Yes - bypasses suppression | Partial - very short half-life |
Prevents testicular atrophy | Limited evidence | Well-established | Limited evidence |
Libido/mood effects | Promising (RCT evidence) | Yes for many men | Insufficient evidence |
FDA/compounding status | Category 2 (restricted, pending reclassification) | Rx available (brand name) | Category 1 (allowable) |
Route | SubQ, IV, intranasal (research) | SubQ injection | SubQ injection |
Nelson Vergel has noted in forum discussions over the years that kisspeptin is not a gonadotropin replacement. Its potential role is distinct: improving central sexual motivation and mood through extrahypothalamic pathways, not substituting for hCG's peripheral testicular effects. These are complementary mechanisms, not competing ones.
What Is the Current Legal and Availability Status of Kisspeptin-10?
The regulatory status of kisspeptin-10 for compounding has been the subject of significant attention in the men's health and peptide communities. Here is the current picture as of May 2026.In late 2023, the FDA moved 19 peptides - including kisspeptin-10 - to Category 2 under the interim 503A bulks list. Category 2 means the FDA has identified 'significant safety risks' pending further evaluation and will not extend the non-enforcement policy that applies to Category 1 substances. In practical terms, 503A compounding pharmacies cannot legally compound kisspeptin-10 under the Category 2 designation. The October 2024 FDA Pharmacy Compounding Advisory Committee (PCAC) meeting specifically reviewed kisspeptin-10 for potential inclusion on the 503A bulks list.
In February 2026, HHS Secretary RFK Jr. announced a plan to reclassify 14 of the 19 restricted peptides back to Category 1 - and kisspeptin-10 is explicitly included in that list. As of May 2026, no formal FDA rulemaking has been published finalizing that reclassification, but the policy direction is clear. Five other peptides were already removed from Category 2 in September 2024 after their nominators withdrew their nominations. If the announced reclassification moves forward, kisspeptin-10 would once again become available from licensed 503A compounding pharmacies with a valid prescription.
Until formal reclassification is finalized, access to compounded kisspeptin-10 in the United States remains legally limited. Any pharmacy offering it under current Category 2 status is operating outside FDA compliance. Monitor the FDA 503A bulks list and ExcelMale forum threads for updates as this regulatory situation continues to evolve.
Frequently Asked Questions About Kisspeptin Peptide
Can kisspeptin improve libido if I am already on TRT with good testosterone levels?
It is possible, but the mechanism would not be hormonal. The 2023 JAMA trial enrolled men with normal testosterone who still experienced low sexual desire - and kisspeptin still improved sexual brain processing and physical arousal. This suggests kisspeptin acts through central behavioral pathways in the brain that exist independently of circulating testosterone levels. For TRT users who have optimized their labs but still struggle with libido, this central pathway is a legitimate area of interest, though TRT-related kisspeptin suppression does limit the signal's upstream potency.What is the difference between kisspeptin-10 and kisspeptin-54?
Kisspeptin-10 (KP-10) is the minimal ten-amino-acid fragment that retains full binding to the KISS1R receptor. It is shorter, potentially more economical to synthesize, and has been widely used in preclinical research. Kisspeptin-54 (KP-54) is the full-length isoform and the most abundant form in humans. It has a longer half-life than KP-10 and has been used in the majority of human clinical trials, including the 2023 JAMA studies and the 2025 intranasal study. KP-54 is generally considered the more clinically relevant form for therapeutic development at this time.Does kisspeptin affect blood pressure the way PT-141 does?
This is a common question from men who experienced significant blood pressure spikes with PT-141 (bremelanotide). Based on available clinical trial data, kisspeptin does not appear to have the same acute cardiovascular effects as PT-141. The 2023 JAMA trial and the 2025 intranasal study both reported no adverse events encountered. However, these trials were conducted in controlled settings and the full blood pressure profile of kisspeptin in men with pre-existing hypertension or cardiovascular risk factors has not been systematically characterized. As with any hormonal or neuropeptide intervention, monitoring by a physician is appropriate.Is kisspeptin being studied for fertility restoration after TRT?
Yes, though this remains primarily in research stages. Because kisspeptin drives GnRH secretion, which in turn stimulates FSH (needed for spermatogenesis), it has theoretical utility for men trying to restore fertility after TRT suppression. Some post-cycle and PCT protocols combine kisspeptin with enclomiphene or gonadorelin for multi-level HPG axis stimulation. The key limitation is that during active TRT, kisspeptin's upstream signal is blunted by negative feedback. Its greatest fertility-related utility is likely in men with secondary hypogonadism who want to preserve axis function without exogenous testosterone, or in post-TRT recovery.How is kisspeptin typically dosed in research studies?
In published intravenous and subcutaneous human studies, doses have typically been weight-based, ranging from 1 to 10 nmol/kg of kisspeptin-54. The 2025 intranasal study used doses of 3.2, 6.4, 12.8, and 25.6 nmol/kg of KP-54, with dose-dependent LH stimulation observed from 6.4 nmol/kg upward and maximal LH rises occurring within 30 minutes. Converting nmol/kg to micrograms depends on molecular weight and body weight - for a 80 kg man, 1 nmol/kg of KP-10 (molecular weight approximately 1302 g/mol) is roughly 104 micrograms. Dosing protocols for off-label clinical use vary widely and are not yet standardized. Any self-administration outside a supervised clinical setting carries significant risks and is not recommended.Related ExcelMale Forum Discussions on Kisspeptin
These forum threads represent years of community discussion on kisspeptin. They are an excellent supplement to the clinical literature above.1. Kisspeptin Suppression Under TRT: Can It Affect Mood and Libido? - The foundational thread exploring how TRT-induced kisspeptin suppression may explain persistent libido and mood issues for some men.
2. Novel Therapeutic Avenues for Kisspeptin - A deep-dive thread covering emerging research on kisspeptin's expanding clinical applications.
3. Kisspeptin Dosage: What the Research Shows - Community discussion on translating nmol/kg research doses into practical microgram amounts.
4. FDA Decides Not to Allow Kisspeptin-10 Manufacturing by Compounding Pharmacies - Thread covering the Category 2 classification and its impact on compounding access.
5. Kisspeptin-10 as a Replacement for Compounded hCG? - Discussion on whether kisspeptin can substitute for hCG during TRT and why it likely cannot.
6. Anyone Succeeding in Increasing Testosterone With Kisspeptin While on TRT? - Member experiences using kisspeptin alongside exogenous testosterone.
7. Kisspeptin-10 Instead of hCG - Practical thread comparing kisspeptin-10 and hCG for men seeking alternatives.
8. Investigating the Detection of Kisspeptin-10 in Urine (Sports/Doping Angle) - Thread covering detection methods relevant to men involved in competitive sports.
Key References
9. Mills EG et al. Effects of kisspeptin on sexual brain processing and penile tumescence in men with hypoactive sexual desire disorder: a randomized clinical trial. JAMA Network Open. 2023;6:e2254313. https://doi.org/10.1001/jamanetworkopen.2022.5431310. Thurston L et al. Effects of kisspeptin administration in women with hypoactive sexual desire disorder: a randomized clinical trial. JAMA Network Open. 2022;5:e2236131. https://doi.org/10.1001/jamanetworkopen.2022.36131
11. Mills EG et al. Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humans. eBioMedicine. 2025;105689. https://doi.org/10.1016/j.ebiom.2025.105689
12. Comninos AN et al. Kisspeptin modulates sexual and emotional brain processing in humans. J Clin Invest. 2017;127:709-719. https://doi.org/10.1172/JCI89519
13. Ertl N et al. Women and men with distressing low sexual desire exhibit sexually dimorphic brain processing. Sci Rep. 2024;14:11051. https://doi.org/10.1038/s41598-024-61547-9
14. Jayasena CN et al. Can kisspeptin be a new treatment for sexual dysfunction? Trends Endocrinol Metab. 2025. https://doi.org/10.1016/j.tem.2025.02.007
15. Navarro VM. Interactions between kisspeptins and neurokinin B. Adv Exp Med Biol. 2013;784:325-347. https://doi.org/10.1007/978-1-4614-6199-9_15
16. Seminara SB et al. The GPR54 gene as a regulator of puberty. N Engl J Med. 2003;349:1614-1627. https://doi.org/10.1056/NEJMoa035322
17. FDA Pharmacy Compounding Advisory Committee Briefing Document: Kisspeptin-10. October 29, 2024. https://www.fda.gov/media/182089/download
18. McBride JA, Coward RM. Recovery of spermatogenesis following testosterone replacement therapy or anabolic-androgenic steroid use. Asian J Androl. 2016;18:373-380. https://doi.org/10.4103/1008-682X.173938
Conclusion: Where Kisspeptin Fits in a Men's Health Protocol
Kisspeptin occupies a unique position in men's hormonal health. It is not a testosterone booster in the conventional sense, and it is not a replacement for hCG. What it represents is the upstream brain-level signal that initiates and modulates the entire reproductive axis - and, critically, that also influences how men process sexual stimuli, motivation, and emotional well-being.The clinical evidence from Imperial College London's randomized trials is now strong enough to take seriously. For men with HSDD who have normal testosterone levels, kisspeptin improved sexual brain processing and penile rigidity meaningfully. The intranasal delivery route opens a practical path that intravenous infusions could not. And while regulatory access remains restricted in the United States as of mid-2026, the announced reclassification signals that kisspeptin-10 compounding access may return in the near term.
For men on TRT who want to explore every variable affecting libido and sexual function, kisspeptin is worth tracking. The ExcelMale forum threads listed above contain years of member-level discussion that complements the peer-reviewed record well. As always, any decision to explore off-label peptide use should involve a knowledgeable physician and baseline blood work.
Medical Disclaimer
This article is for educational purposes only and does not constitute medical advice. Kisspeptin-10 is not FDA-approved for any indication and its compounding status under 503A is currently restricted. Always consult a qualified healthcare provider before starting or modifying any hormone therapy, peptide protocol, or medical treatment. References to regulatory developments reflect information available as of May 2026 and are subject to change.
About ExcelMale.com
ExcelMale.com is one of the world's largest and most respected men's health forums, with over 24,000 members and more than 20 years of peer-moderated discussion on testosterone replacement therapy, hormone optimization, peptides, sexual health, and longevity. The forum was founded and is curated by Nelson Vergel, chemical engineer, 30+ year TRT patient, and author of Testosterone: A Man's Guide and Beyond Testosterone. Nelson's work bridges peer-reviewed research and real-world patient experience in a way that no purely academic source can match.
Last edited by a moderator:
